A Randomized, Crossover Phase 1 Study to Evaluate the Effects of Pevonedistat on the QTc Interval in Patients With Advanced Solid Tumors

Trial Profile

A Randomized, Crossover Phase 1 Study to Evaluate the Effects of Pevonedistat on the QTc Interval in Patients With Advanced Solid Tumors

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Pevonedistat (Primary) ; Carboplatin; Docetaxel; Paclitaxel
  • Indications Solid tumours
  • Focus Pharmacodynamics
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 09 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top